Clinical trial
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line…
NCT00327340 · Achieve Life Sciences, Industry · Completed
Key facts
| NCT number | NCT00327340 |
|---|---|
| Title | Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC |
| Official title | Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | Achieve Life Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel |
| Enrollment | 70 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | May 18, 2006 |
| Last update posted | Oct 5, 2012 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: